Retrospective analysis of stage IV advanced gastric cancer treated with S-1 or other chemotherapy

International Journal of Clinical Oncology

Volumn 11, Issue 5, 2006, Pages 367-374

  Shitara, Kohei ^a   Ishiguro, Atushi ^a   Munakata, Masaki ^a   Wada, Ryouichi ^b   Sakata, Yuh ^a  

^a Misawa City Hospital   (Japan)

^b KAMEDA MEDICAL CENTER   (Japan)

Author keywords

Prognostic factor; S 1; Second line chemotherapy; Stage IV gastric cancer

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; BILIRUBIN; CISPLATIN; CREATINE; FLUOROURACIL; IRINOTECAN; METHOTREXATE; PACLITAXEL; TEGAFUR; UFT; URACIL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG COMBINATIONS; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TEGAFUR; TREATMENT OUTCOME;

EID: 33750284874     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-006-0588-z     Document Type: Article

References (21)

1. T Shirasaka Y Shimamato H Ohshimo 1996 Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548 557
2. W Koizumi M Kurihara S Nakano 2000 Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer Oncology 58 191 197
3. Y Sakata A Ohtsu N Horikoshi 1998 Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1∈M tegafur 0.4∈M gimestat 1∈M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715 1720
4. H Takiuchi M Goto S Kawabe 2005 Second-line chemotherapy in gastric cancer (in Japanese) Japanese Journal of Cancer and Chemotherapy 32 19 23
5. K Yonemori Y Shimada A Goto 2004 Retrospective analysis of clinical results and predictors of response in chemo-naive patients with advanced gastric cancer treated with S-1, an oral fluoropyrimidine derivative, as single-agent chemotherapy Gastric Cancer 7 204 210
6. Japanese Research Society for Gastric Cancer 1999 Japanese classification of gastric carcinoma Kanehara Tokyo
7. Japanese Gastric Cancer Association 2001 Japanese classification of gastric carcinoma. 2nd English edition. Response assessment of chemotherapy and radiotherapy for gastric carcinoma: clinical criteria Gastric Cancer 4 1 8
8. S Takeno T Noguchi R Kikuchi 2001 Analysis of the survival period in resectable stage IV gastric cancer Ann Surg Oncol 8 215 221
9. M Yoshida N Boku A Ohtsu 2001 Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice Gastric Cancer 4 144 149
10. Y Kakeji Y Maehara M Tomoda 1998 Long-term survival of patients with stage IV gastric carcinoma Cancer 82 2307 2311
11. Dong-Yi Kim Jae-Kyoon Joo Seong-Yeob Ryu 2005 Clinicopathologic characteristics of gastric carcinoma in elderly patients: a comparison with young patients World J Gastroenterol 11 22 26
12. C Louvet F Carrat F Mal 2003 Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil and cisplatin Cancer Invest 21 14 20
13. H Baba T Okuyama O Hiroyuki 1992 Prognostic factors for noncurative gastric cancer: univariate and multivariate analyses J Surg Oncol 51 104 108
14. PO Sjoden U Haglund C Svensson 1997 Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 8 163 168
15. A Ohtsu Y Shimada K Shirao 2003 Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG 9205) J Clin Oncol 21 54 59
16. A Grothey D Sargent RM Goldberg 2004 Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment J Clin Oncol 22 1209 1214
17. W Koizumi S Tanabe A Ohtsu 2003 Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer Br J Cancer 89 2207 2212
18. Yoshida K, Toge T, Nishiyama M, et al. (2005) Phase II study of S-1 and docetaxel combination in advanced or recurrent gastric cancer. 41st ASCO meeting Proc #4049, P320
19. I Hyodo K Ymaguchi Y Sakata 2005 Phase I/II study of docetaxel and S-1 for patients with advanced gastric cancer J Clin Oncol (Meeting Abstracts) 23 4064
20. Y Komatsu S Yuuki Y Sakata 2004 Phase I/II clinical study of irinotecan plus S-1 in patients with advanced gastric cancer J Clin Oncol (Meeting Abstracts) 22 4191
21. A Ohtsu 2005 Current status and future prospects of chemotherapy for metastatic gastric cancer: a review Gastric Cancer 8 95 102